Signant Health has expanded its mobile patient engagement app, TrialGuide, with integrated virtual visit capabilities.

Initially launched to aid existing customers dealing with the patient-site communication challenges presented by Covid-19, virtual visits have been extended for all sponsors and CROs as the firm continues to speed up its product development roadmap to meet the evolving requirements of clinical research across the world.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Virtual visits offer more choice for patients and clinicians in enhancing the patient experience and supporting trial continuity, now and in the future.

By bringing together virtual face-to-face communication with right remote evaluations, and a direct to patient clinical supply chain, Signant Health claims to offer flexibility for patients, sites, and study teams on how, and where, clinical research is carried out.

A patient engagement solution, TrialGuide comes with features that complement virtual visits, including SMS messaging, compliance reminders, visit schedule management, caregiver support, multimedia and animated content, gamification, third-party integration with patient stipend balances, and rapid deployment capabilities.

In addition to patient engagement, Signant Health’s combined suite of patient solutions, including clinical supply chain management and endpoint quality services, are claimed to have aided customers overcome the unforeseen challenges presented by Covid-19 and prepare for new realities in clinical research by aiding trial continuity and launching clinical trials faster than before.

Signant Health chief commercial officer Ian Jennings said: “The Covid-19 pandemic illustrated how important patient-site connectivity is to the success of clinical research and our goal is to make it easier for patients to participate and communicate in trials without the technology getting in their way.

“Whether that means enabling eCOA data capture, remote consent, and video visits on a single device, deploying IRT in record time to randomise and supply patients as quickly as possible, or equipping raters with the training and tools they need to make consistent assessments remotely, we are here to support our customers who are working hard to keep their trials running and bring new treatments to people who need them worldwide.”